Diligence memo · auto-generated · as of July 2, 2026

Asset Blue Pharmacy Services, Inc.

Asset Blue Pharmacy Services, Inc. looks under-valued against its niche peers and is active on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Asset Blue Pharmacy Services, Inc. operates in Biotech / Pharma, based in CHICAGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Asset Blue Pharmacy Services, Inc. has raised $48M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $28M on 2022-01-14.

Most recent recorded round closed around 2024-11-26.

Valuation (modeled)modeled

Provath models Asset Blue Pharmacy Services, Inc. at approximately $105M (range $36M–$173M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.40× the median modeled value of Series B Biotech / Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 20 months.

Last raise 19 mo ago; this sector typically re-raises about every 15 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 1.6× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 88% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 70% of those peers.

Closest niche peers: Carbon Biosciences, Inc., Slingshot Biosciences, Inc., Nueva Bio LLC, Telesis Bio Inc., Turn Biotechnologies, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.